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1116-32 Getting Risk Factors to Goal: Lifestyle Intervention Is 
Worth the Effort in Patients With Hypertension, 
Hyperlipidemia, and/or Hyperglycemia
Neil F. Gordon, Richard D. Salmon, William E. Saxon, Kevin S. Reid, George C. Faircloth, 
Ivan Levinrad, Brenda S. Mitchell, Richard F. Leighton, Laurence S. Sperling, William L. 
Haskell, Barry A. Franklin, St. Joseph's/Candler Health System, Savannah, GA, 
INTERVENT Coordinating Center, Savannah, GA
Background: Hypertension, hyperlipidemia, and hyperglycemia are leading causes of
potentially avoidable morbidity, mortality, and healthcare expenditures. National clinical
guidelines promulgate therapeutic lifestyle changes (TLC) as a standard of care in the
management of these cardiovascular disease risk factors. Because of the widespread
availability of pharmacotherapeutic agents, however, the value of TLC per se in contem-
porary medical practice is often discounted by clinicians and health insurers. The aim of
this study was to evaluate the precise role of TLC in helping patients achieve goal risk
factor levels.
Methods: We studied the effect of TLC on the control of: blood pressure (BP) in unmedi-
cated patients with a baseline systolic BP > 140 mmHg (n=335) and/or diastolic BP > 90
mmHg (n=346); LDL cholesterol in unmedicated patients with a baseline value > 100 mg/
dl (n = 1,553); and fasting blood glucose in unmedicated patients with a baseline value >
110 mg/dl (n=249). TLC included exercise training and nutrition counseling. Interventions
were based on several well established behavior change models. Patients remained
unmedicated throughout the study and were evaluated at baseline and after 3 months of
TLC.
Results: Systolic BP decreased from 149 + 10 to 133 + 15 mmHg (p<0.05) and 63% of
patients achieved goal (i.e., <130 mmHg for patients with diabetes and/or atherosclero-
sis; <140 mmHg for others). Diastolic BP decreased from 95 + 5 to 85 + 9 mmHg
(p<0.05) and 65% of patients achieved goal (i.e., <80 mmHg for patients with diabetes;
<85 mmHg for patients with atherosclerosis; <90 mmHg for others). LDL cholesterol
decreased from 143 + 28 to 134 + 30 mg/dl (p<0.05) and 27% of patients achieved goal
(using ATP III criteria). Fasting glucose decreased from 144 + 43 to 129 + 43 mg/dl and
41% of patients achieved goal (i.e. <110 mg/dl); of patients with a baseline value compat-
ible with diabetes (i.e., >125 mg/dl; n=141), 35% achieved a value <125 mg/dl.
Conclusion: These data show that many patients with classic cardiovascular disease
risk factors can achieve goal without medications within 3 months of initiating TLC and
refute the notion that intensive lifestyle intervention is not worth the effort.
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1116-33A Effect of Lipid Subfractions on Progression of Coronary 
Artery Disease Among Middle-Aged Women
Adhir Shroff, Kristina Orth-Gomer, Julia Fridman, Imre Janszky, Bertil Svane, Richard L. 
Kirkeeide, Karin Schenck-Gustafsson, Murray A. Mittleman, Beth Israel Deaconess 
Medical Center, Boston, MA, Karolinska Institutet, Stockholm, Sweden
Background: As part of the Stockholm Female Coronary Risk Study we studied the
effects of lipid parameters on progression of CAD among a cohort of 84 women who
were 65 years or younger with established CAD, not taking lipid lowering medications,
and underwent serial quantitative coronary angiography (QCA) at baseline (between
1991-1994) and after 3 years.
Methods: An average of 3 months after an acute coronary syndrome the women sup-
plied clinical and demographic data and a fasting blood sample. The association between
each lipid parameter and change in mean luminal diameter in up to 10 coronary seg-
ments was estimated using multivariable mixed model analysis of variance controlling for
age, index event, diabetes, hypertension, smoking, BMI, menopausal status, and hor-
mone use.
Results: There were 568 evaluable coronary segments among the 84 women. The table
shows that each of the standard lipid parameters (total cholesterol, LDL, HDL, triglycer-
ides) and apolipoprotiens (ApoB, ApoA1, VLDL) significantly predicted progression while
Lp(a) did not. The strongest and most consistent associations were found for non-HDL
cholesterol and the ratio chol:HDL. Furthermore, after including either non-HDL choles-
terol or chol:HDL in the model, none of the other lipid parameters significantly improved
the prediction of CAD progression.
Conclusion: Non-HDL cholesterol and the ratio of chol:HDL were the best predictors of
progression of CAD among this cohort of middle-aged women with established disease.
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1116-33 Renal Transplant Function as a Risk Factor for 
Cardiovascular Events and for All Cause Mortality in a 
Renal Transplant Population: Experience From the 
ALERT Trial
Bengt Fellström, H. Holdaas, A. Jardine, E. Cole, G. Nyberg, C. Gronhagen-Riska, S. 
Madsen, H. Neumayer, B. Maes, P. Ambuhl, I. Holme, P. Faucald, T. Pedersen, The 
ALERT Study Investigators, University Hospital, Uppsala, Sweden
Background: ALERT was a randomized, placebo-controlled, study of the effects of Fluv-
astatin on cardiovascular and renal endpoints in transplant recipients with a stable renal
function followed for 5-6 years. The design and major outcomes have been published
(Lancet, June 14, 2003). In this population the role of conventional cardiac risk factor has
not been fully established. Methods: A univariate risk factor analysis was performed in
the placebo group to assess the influence of creatinine as a risk factor for cardiovascular
and non cardiovascular endpoints. Results: A total of 2102 patients ( total cholesterol
155-348 mg/dl) were recruited, of whom 1052 received placebo. The mean age was 50
years ( 30-75) , 66% male, 85% first transplant recipients and 22 % live donor recipients.
The average serum creatinine at inclusion was 147 umol/l (range 70- 300).The relative
risk for a 10 unit increase in creatinine and the frequency of events in the 1st quartile
(<111 umol/L) compared with the 4th Q ( >167 umol/L) are presented : 
*MACE (Major Adverse Cardiac Event: cardiac death, MI, revascularization procedure)
Conclusion: In renal transplant recipients with stable function, serum creatinine is a risk 
factor for MACE, cardiac death, cardiac death, non-cardiovascular mortality and all cause 
mortality but not for stroke or non-fatal myocardial infarction. These findings are borne 
out in multivariate analyses adjusting for other cardiovascular risk factors.
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1116-34 Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme a 
Reductase Attenuates Expression of Inducible Nitric 
Oxide Synthase in Cardiac Myocytes: A Possible Link 
With Direct Myocardial Protection During Ischemia-
Reperfusion
Rosalinda Madonna, Pericle Di Napoli, Marika Massaro, Alfredo Grilli, Mario Felaco, 
Yong-Jian Geng, Rafffaele De Caterina, University of Chieti, Cardiology Division, Chieti, 
Italy
Cytokine-induced nitric oxide (NO) is implicated in myocardial apoptosis. Since statins
reduce myocardial apoptosis, we examined the effects of simvastatin (S) on inducible NO
synthase (iNOS) expression in cardiac myocytes, which may explain cardioprotection
observed in in vivo models. H9c2 cardiac myocytes were treated with S ± mevalonate (10
–
4
 mol/L), geranyl-geranyl-pyrophosphate or farnesyl-pyrophosphate (10 –4 mol/L) for 30
min, then stimulated for 0 - 48 h with interleukin (IL)-1α 20 ng/mL or tumor necrosis factor
(TNF)-α 20 ng/mL. Untreated H9c2 cells exhibited little iNOS which was markedly
increased by cytokines, as demonstrated by immunoblotting and nitrite assay. In the
absence of any cytotoxicity S concentration-dependently inhibited IL-1α/TNF-α-induced
expression of iNOS protein and mRNA (measured by reverse-transcrition polymerase
chain reaction), as well as nitrite production, an effect starting at 10-7 mol/L for IL-1α/
TNF-α stimulation of iNOS activity and protein expression, and at 10-8 mol/L for IL-1α/
TNF-α stimulation of iNOS mRNA expression, effects all reverted by mevalonate and ger-
anyl-geranyl pyrophosphate, but not by farnesyl-pyrophosphate. In the Table: *p<.05 vs
Multivariable Adjusted Mean Lumen Diameter Progression (um)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
Total Chol 109 61 135 258 0.01
LDL 81 35 171 164 0.02
HDL 246 107 177 61 0.002
Triglycerides 80 126 135 237 0.005
ApoB 75 91 142 258 0.004
ApoA1 238 53 184 73 0.04
VLDL 60 103 154 223 0.002
Lp(a) 169 100 91 136 0.48
Chol:HDL 47 80 190 211 0.0002
ApoB:ApoA1 30 148 21 287 0.004
Non-HDL-C 20 140 133 287 <0.0001
End point Relative
Risk




MACE 1.05 1.02-1.08 0.0007 11.5% 16.0%
Cardiac Death 1.03 1.05-1.13 <0.0001 4.2% 8.0%
Non fatal MI 1.01 0.96-1.06 0.6426 6.5 % 6.3 %
Stroke 1.03 0.97-1.08 0.3550 5.8% 5.5%
All Cause Mortality 1.01 1.01-1.01 <0.0001 11.2% 22.7%
Non-CV Mortality 1.01 1.00-1.01 0.0005 5.4% 10.1%









basal; ** p<.05 vs cytokine without S; #p<.05 vs S+TNF or S+IL. In conclusion, at clini-
cally achievable concentrations S inhibits iNOS expression by inhibiting geranyl-gerany-
lation of a protein controlling iNOS expression. Such effect may contribute to
cardioprotection against excess NO production.
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1116-35 Histopathological Study of Left Atrial Appendage 
Obtained at the Operation for Atrial Fibrillation
Tsunenori Saito, Daisuke Uchida, Tomonari Saito, Koichi Tamura, Yuichi Sugisaki, 
Nippon Medical School, Tokyo, Japan
Background: Surgical procedure for atrial fibrillation (AF) is an effective treatment. Patho-
logical changes of resected left atrial appendages (LAA) have not been studied. The cor-
relation between histological changes of LAA and clinical features of AF was evaluated.
Also, we investigated whether histological assessments of LAA prospect the recurrence
after the operation for AF.
Methods: Clinicopathological studies were made on 53 AF cases (49 biopsies and 4
autopsies: 46 - 83 years; 51 with and 2 without valvular disease) and 39 control autopsy
cases with sinus rhythm (5 with and 34 without valvular disease, 42 - 86 years). Together
with histopathological examination, cell size, nuclear size and shape, and % fibrosis in
LAA were evaluated using NIH image system. Histological findings were compared with
clinical features, including left atrial dimension (LAD), pulmonary capillary wedge pres-
sure, duration of clinical history of AF and that of basal diseases, and cardiac rhythm
after the operation. Results were analyzed by Chi square test or Fisher’s exact method.
Results: The partial disarray of cardiomyocytes was recognized in both AF and control
groups. Compared with control, LAA with AF showed hypertrophy of cardiomyocytes (p <
0.001), nuclear enlargement (p < 0.001), bizarre nuclear shape (BN) (p < 0.001), and
intercellular fibrosis (ICF) (p < 0.001) . Long clinical history (> 10 years) of AF resulted in
larger number of BN (p < 0.025) and more extensive ICF (p < 0.05). The patients with
larger LAD had more extensive ICF (p < 0.05). Among AF group, cases with mitral steno-
sis had larger cell size (p < 0.025) and more extensive ICF (p < 0.001) than those with
other valvular disease. Cases with recurrent AF after the operation had more cellular
hypertrophy (p < 0.01), nuclear enlargement (p < 0.01), BN (p < 0.01), and ICF (p < 0.01)
than others.
Conclusion: The histopathological findings of LAA reflect basal diseases and the duration
of AF. However, recurrence of AF after the operation is thought to be predictable from the
histological findings of bizarre nuclear shape and extensive intercellular fibrosis in LAA.
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1116-36 Prognostic Implications of Nonsustained Ventricular 
Tachycardia Early After ST Elevation Myocardial 
Infarction Treated With Fibrinolysis or Primary 
Angioplasty
Dan E. Hofsten, Kenneth Egstrup, Birgit Lund, Henning Molgaard, for the DANAMI-2 
investigators, Svendborg Hospital, Svendborg, Denmark, Skejby Sygehus, Aarhus 
University Hospital, Aarhus, Denmark
Background: The prognostic features of nonsustained ventricular tachycardia (nsVT)
detected on Holter monitoring after ST-segment elevation myocardial infarction (STEMI)
treated with primary angioplasty (PA) remains uncertain. We compared the prevalence
and prognostic implications of nsVT detected early after STEMI treated with either fibrin-
olysis or PA.
Methods: Twenty four hour Holter monitoring was initiated at discharge from STEMI in
1,157 patients who had been randomized to immediate revascularization with either
fibrinolysis (n = 575) or PA (n = 582) as part of the DANAMI-2 study. The definition of
nsVT was > 3 consecutive ventricular premature beats with an RR interval < 600 ms. Fol-
low-up ranged from 2 to 5 years. Primary end point was all-cause mortality.
Results: The incidence of nsVT was 9.4% in both treatment groups (p = 0.97). Univari-
ate analyses showed a significantly increased mortality associated with nsVT in fibrinoly-
sed patients (hazard ratio: 3.2; p < 0.001), but only a smaller, and non-significant, trend in
the PA group (hazard ratio: 2.2; p = 0.085).
In a stepwise multivariate Cox regression analysis incorporating clinical and investiga-
tional variables, nsVT was independently correlated to outcome after fibrinolysis (p =
0.025) but not after PA (p = 0.64).
Conclusion: The use of PA in STEMI does not affect the subsequent incidence of nsVT
as compared to fibrinolysis. However, unlike in fibrinolysed patients, nsVT is not an inde-
pendent predictor of outcome after primary angioplasty.
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1116-37 Use of the Implantable Loop Recorder in the Diagnosis 
and Management of Syncope: Long-Term Follow-Up
David J. Farwell, Nick Freemantle, Neil Sulke, Eastbourne General Hospital, Eastbourne, 
United Kingdom
Background: Implantable loop recorders (ILR) provide an opportunity to record ECG
data from a spontaneous syncopal event. We conducted a randomised study to investi-
gate the impact of the Reveal Plus ILR on an unselected population of patients with
recurrent syncope. Initial follow-up (reported ACC 2002) failed to demonstrate a reduc-
tion in syncopal events or an improvement in quality of life. We continued follow-up for a
further year in all patients.
Methods: All patients presenting acutely with recurrent unexplained syncope over a 16-
month period, following a basic clinical work up, were randomised to receive the ILR or
conventional investigation.
Results: 421 patients presented, 201 were eligible, median age 74 (IQ range 61-81)
54% female, with median syncopes 3 (IQ range 2-6). Median follow up 17 months (IQ
range 9-23). There were no significant differences between groups at randomisation.
42% of ILR patients and 8% of conventional patients received an ECG diagnosis (Hazard
ratio 4.9 95%CI 2.3-12.1). Time to 2nd syncope was increased in ILR patients (Hazard
ratio 2.2 95%CI 1.2-4.2). A greater variety of diagnoses and treatments were seen in ILR
patients. ILR patients had fewer post randomisation investigations and fewer days in hos-
pital, however cost savings were not statistically significant. There was a trend towards
improved quality of life in the ILR group with significant increase in visual/ analogue
scale/scores (p=0.033), no change was noted in SF-12 scores. Overall mortality was
12% with no difference between groups.
Conclusions: Investigation by ILR significantly increases the number of diagnoses and
treatments available to a typical syncopal population. Long-term follow up shows reduc-
tion in syncopal events with improved quality of life in patients investigated with an ILR.
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1116-38 Selection of Optimal Electrocardiographic Criteria for 
Detection of Unrecognized Myocardial Infarction: A 
Population Based Study
Khawaja A. Ammar, Barbara P. Yawn, Jan A. Kors, Steven Jacobsen, Lynn Urban, 
Douglas Mahoney, Richard J. Rodeheffer, Mayo Clinic, Rochester, MN, Olmsted Medical 
Center, Rochester, MN
Background: Unrecognized Myocardial Infarctions (UMIs) are fairly common and have a
prognosis similar to that of acute recognized myocardial infarctions. Surveillance electro-
cardiograms in population-based studies identify UMI. It has been shown that the wide
variation in UMI prevalence (20 to 44% of all MI) may be due to variations in ECG-MI cri-
teria used in various studies. We sought to find the best possible ECG criteria for detec-
tion of UMI, since it has both individual and public health implications. To the best of our
knowledge, this goal has never been undertaken before.
Methods: A random sample of 4203 out of 106400 Olmsted County residents, >45 years
of age were invited to participate. 2042 completed the survey consisting of detailed his-
tory, physical exam, medical record abstraction, ECG and echocardiogram. Six different
ECG-MI criteria (from different published studies), all based on Minnesota Code, were
applied to the same survey ECG and UMI prevalence was estimated. The operating test
characteristics of different criteria were compared against the gold standard of either a
documented, hospitalized MI or an MI confirmed by presence of regional wall motion
abnormalites by echocardiogram.
Results: The UMI proportion, relative to all myocardial infarctions, varied from 29% to
60%. The sensitivity and specificity of different ECG criteria varied between 19% to 32%
and 92% to 98% respectively, with multiple statistically significant differences (p values of
0.0001). The specificity improved with increasing width and height of Q waves, wheras
the sensitivity was enhanced by step-wise inclusion of minor Q, and major ST or T wave
abnormality, at the incremental cost of specificity. Enhancing the diagnostic performance
of ECG by exclusion of poor R wave progression as a criterion for ECG-MI, in patients
with severe emphysema or severe obesity, did not make a difference.
Conclusions: In our study, the best performance was displayed by ECG criteria used in
the Cardiovascular Health Study, with a near maximum sensitivity and specificity of 26%
and 96%, respectively. These incorporated major Q-waves as stand alone, and minor Q
waves only if accompanied by concomitant ST and T wave abnormalites.
iNOS protein expression (arbitrary densitometric units), expressed as mean ± SD, 
n=3 experiments
basal (untreated cells) 34±5 basal (untreated cells) 45±4
IL 160± 5* TNF 120±9*
IL+S 10-8 71±5** TNF+S 10-8 65±18**
IL+S108+ Mev 56±8 TNF+S 10-8 + Mev 77±10
IL+S 10-7 42±10** TNF+S 10-7 48±13**
IL+S 10-7 + Mev 106±10# TNF+S 10-7 + Mev 105±8#
IL+S 10-6 20±4** TNF+S 10-6 33±3**
IL+S 10-6 + Mev 131±14# TNF+S 10-6 + Mev 75±8#
